CHANGES OF INTERLEUKINS IN PATIENTS WITH NOSOCOMIAL PNEUMONIA AGAINST A BACKGROUND OF TRAUMATIC BRAIN INJURY: ROLE IN THE DIAGNOSIS AND MONITORING OF DISEASE
Abstract
Introduction. Nosocomial pneumonia (NP) is the second leading frequency and mortality among nosocomial infections. NP is a frequent complication of severe traumatic brain injury (TBI). The difficulty in diagnosis and monitoring of disease NP on the background of TBI is that the usual signs NP "masked" manifestations of the underlying disease.
The aim of our study was to improve the diagnosis and assess the effectiveness of the treatment of nosocomial pneumonia with clarithromycin by studying of serum interleukins in patients with nosocomial pneumonia on the background of traumatic brain injury.
Materials and methods. We determined levels of TNFα, IL-4, IL-6, IL-8, IL-10. We examined 45 patients with isolated TBI, 44 patients with NP (standard treatment scheme), 49 patients with NP, each therapy with clarithromycin. The control group was 33 relatively healthy people.
Conclusions. The study revealed a significant increase in the concentration of interleukin TNFα, IL-6, IL-8, IL-10 in the serum of patients with NP on the background of TBI compared with patients with isolated TBI and healthy individuals. Our study found significantly lower concentrations of interleukin TNFα, IL-6, IL-8, IL-10 in the serum of patients after treatment with the addition of clarithromycin compared with patients with standard therapy.
Downloads
References
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia (2005). American Journal of Respiratory and Critical Care Medicine, 171 (4), 388–416. doi: 10.1164/rccm.200405-644st
Barbier, F., Andremont, A., Wolff, M., Bouadma, L. (2013). Hospital-acquired pneumonia and ventilator-associated pneumonia. Current Opinion in Pulmonary Medicine, 19 (3), 216–228. doi: 10.1097/mcp.0b013e32835f27be
Chuchalin, A. G. (2015). Pneumonia as an actual medical problem of the 21th century. Pulmonology, 25 (2), 133–142. doi: 10.18093/0869-0189-2015-25-2-133-142
Feshchenko, Yu. I., Dziublyk, Yu. I., Simonov, S. S. (2012). Hospitalna (nozokomialna) pnevmoniia u doroslykh osib: etiolohiia, patohenez, klasyfikatsiia, diahnostyka, antybakterialna terapiia [Hospital (nosocomial) pneumonia in adults: etiology, pathogenesis, classification, diagnosis, antibiotic therapy]. Zdorovia Ukrainy, 1 (278), 35–36.
Giamarellos-Bourboulis, E. J., Mylona, V., Antonopoulou, A., Tsangaris, I., Koutelidakis, I., Marioli, A. et. al. (2013). Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 69 (4), 1111–1118. doi: 10.1093/jac/dkt475
Gogos, C. A., Drosou, E., Bassaris, H. P., Skoutelis, A. (2000). Pro‐versus Anti‐inflammatory Cytokine Profile in Patients with Severe Sepsis: A Marker for Prognosis and Future Therapeutic Options. The Journal of Infectious Diseases, 181 (1), 176–180. doi: 10.1086/315214
Patella, M., Anile, M., Del Porto, P., Diso, D., Pecoraro, Y., Onorati, I. et. al. (2014). Role of cytokine profile in the differential diagnosis between acute lung rejection and pulmonary infections after lung transplantation. European Journal of Cardio-Thoracic Surgery, 47 (6), 1031–1036. doi: 10.1093/ejcts/ezu395
Abouelela, A., Al-Badawy, T., Abdel Gawad, M. (2015). Predictive value of different scoring systems for critically ill patients with hospital acquired pneumonia. Intensive Care Medicine Experimental, 3 (1), A345–A347. doi: 10.1186/2197-425x-3-s1-a345
Rotstein, C., Evans, G., Born, A., Grossman, R., Light, R. B., Magder, S. et. al. (2008). Clinical Practice Guidelines for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 19 (1), 19–53. doi: 10.1155/2008/593289
Rice, T. W., Wheeler, A. P., Morris, P. E., Paz, H. L., Russell, J. A., Edens, T. R., Bernard, G. R. (2006). Safety and efficacy of affinity-purified, anti–tumor necrosis factor-α, ovine fab for injection (CytoFab) in severe sepsis. Critical Care Medicine, 34 (9), 2271–2281. doi: 10.1097/01.ccm.0000230385.82679.34
Spyridaki, A., Raftogiannis, M., Antonopoulou, A., Tsaganos, T., Routsi, C., Baziaka, F. et. al. (2012). Effect of Clarithromycin in Inflammatory Markers of Patients with Ventilator-Associated Pneumonia and Sepsis Caused by Gram-Negative Bacteria: Results from a Randomized Clinical Study. Antimicrobial Agents and Chemotherapy, 56 (7), 3819–3825. doi: 10.1128/aac.05798-11
Taylor, G., Gravel, D., Matlow, A., Embree, J., LeSaux, N. et. al. (2016). Assessing the magnitude and trends in hospital acquired infections in Canadian hospitals through sequential point prevalence surveys. Antimicrobial Resistance & Infection Control, 5 (1), 19–25. doi: 10.1186/s13756-016-0118-3
Tsaganos, T., Raftogiannis, M., Pratikaki, M., Christodoulou, S., Kotanidou, A., Papadomichelakis, E. et. al. (2016). Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. Antimicrobial Agents and Chemotherapy, 60 (6), 3640–3646. doi: 10.1128/aac.02974-15
Gikas, A., Roumbelaki, M., Bagatzouni-Pieridou, D., Alexandrou, M., Zinieri, V., Dimitriadis, I., Kritsotakis, E. I. (2010). Device-associated infections in the intensive care units of Cyprus: results of the first national incidence study. Infection, 38 (3), 165–171. doi: 10.1007/s15010-010-0007-2
Xia, J., Gao, J., Tang, W. (2016). Nosocomial infection and its molecular mechanisms of antibiotic resistance. BioScience Trends, 10 (1), 14–21. doi: 10.5582/bst.2016.01020
Kollef, M. H., Hamilton, C. W., Ernst, F. R. (2012). Economic Impact of Ventilator-Associated Pneumonia in a Large Matched Cohort. Infection Control & Hospital Epidemiology, 33 (03), 250–256. doi: 10.1086/664049
Van Vught, L. A., Scicluna, B. P., Wiewel, M. A., Hoogendijk, A. J., Klein Klouwenberg, P. M. C., Franitza, M. et. al. (2016). Comparative Analysis of the Host Response to Community-acquired and Hospital-acquired Pneumonia in Critically Ill Patients. American Journal of Respiratory and Critical Care Medicine, 194 (11), 128–133. doi: 10.1164/rccm.201602-0368oc
Micek, S. T., Chew, B., Hampton, N., Kollef, M. H. (2016). A Case-Control Study Assessing the Impact of Nonventilated Hospital-Acquired Pneumonia on Patient Outcomes. Chest, 150 (5), 1008–1014. doi: 10.1016/j.chest.2016.04.009
Mouktaroudi, M., Giamarellos-Bourboulis, E. J. (2012). Macrolides for the therapy of nosocomial infections. Current Opinion in Infectious Diseases, 25 (2), 205–210. doi: 10.1097/qco.0b013e32834ff1b4
Radzikowska, E., Roży, A., Jaguś, P., Wiatr, E., Gawryluk, D., Chorostowska-Wynimko, J., Roszkowski-Śliż, K. (2016). Cryptogenic Organizing Pneumonia: IL-1β, IL-6, IL-8, and TGF- β1 Serum Concentrations and Response to Clarithromycin Treatment. Advances in Respiratory Cancerogenesis, 911, 77–85. doi: 10.1007/5584_2016_223
Zilberberg, M. D., Shorr, A. F. (2010). Ventilator‐Associated Pneumonia: The Clinical Pulmonary Infection Score as a Surrogate for Diagnostics and Outcome. Clinical Infectious Diseases, 51 (S1), S131–S135. doi: 10.1086/653062
Zeng, M., Li, Z.-Y., Ma, J., Cao, P.-P., Wang, H., Cui, Y.-H., Liu, Z. (2015). Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model study. BMC Immunology, 16 (1), 16–37. doi: 10.1186/s12865-015-0096-x
Eachempati, S. R., Hydo, L. J., Shou, J., Barie, P. S. (2010). The Pathogen of Ventilator-Associated Pneumonia Does Not Influence the Mortality Rate of Surgical Intensive Care Unit Patients Treated with a Rotational Antibiotic System. Surgical Infections, 11 (1), 13–20. doi: 10.1089/sur.2008.025
Copyright (c) 2017 Anastasiia Ilchenko
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
